We validated that the inhibition of the DNA repair pathway can increase sensitivity to T-DXd treatment in TDM-1 resistant and T-DXd resistant BC in vitro and in vivo. This preclinical study provides justification for conducting clinical trials with HER2+ BC patients who develop resistance to T-DM1 or T-DXd treatment. Here, ERBB2 is linked to breast cancer.